Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATOSNASDAQ:PIRSNASDAQ:RVLP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Therapeutics$1.37-3.5%$1.39$0.59▼$2.31$171.67M1.21.40 million shs1.21 million shsPIRSPieris Pharmaceuticals$0.15-6.5%$0.17$0.14▼$1.01$14.35M0.48580,219 shs1.92 million shsRVLPRVL Pharmaceuticals$0.04$0.03▼$1.91N/AN/AN/A63.96 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Therapeutics+5.19%-19.77%-8.39%+73.17%+90.71%PIRSPieris Pharmaceuticals-1.34%-12.63%-28.07%-7.02%-81.33%RVLPRVL Pharmaceuticals0.00%0.00%0.00%0.00%-97.18%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Therapeutics1.3154 of 5 stars3.51.00.00.02.91.70.0PIRSPieris Pharmaceuticals0.4674 of 5 stars0.03.00.04.60.00.80.6RVLPRVL PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Therapeutics3.00Buy$4.50228.47% UpsidePIRSPieris Pharmaceuticals2.00HoldN/AN/ARVLPRVL Pharmaceuticals3.00Buy$2.50∞ UpsideCurrent Analyst RatingsLatest ATOS, RVLP, and PIRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/APIRSPieris Pharmaceuticals$42.81M0.34N/AN/A$0.27 per share0.54RVLPRVL Pharmaceuticals$49.72M0.00N/AN/A$0.51 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)PIRSPieris Pharmaceuticals-$24.54M-$0.28N/AN/AN/A-57.33%-90.17%-38.12%5/8/2024 (Estimated)RVLPRVL Pharmaceuticals-$51.69M-$0.700.00N/AN/AN/AN/AN/A5/9/2024 (Estimated)Latest ATOS, RVLP, and PIRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A3/29/2024Q4 2023PIRSPieris PharmaceuticalsN/A-$0.05-$0.05-$0.06N/A$1.30 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa TherapeuticsN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ARVLPRVL PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa TherapeuticsN/A17.6117.61PIRSPieris PharmaceuticalsN/A3.243.24RVLPRVL PharmaceuticalsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Therapeutics12.74%PIRSPieris Pharmaceuticals40.11%RVLPRVL Pharmaceuticals14.36%Insider OwnershipCompanyInsider OwnershipATOSAtossa Therapeutics7.80%PIRSPieris Pharmaceuticals8.89%RVLPRVL Pharmaceuticals4.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Therapeutics11125.30 million115.53 millionOptionablePIRSPieris Pharmaceuticals4698.93 million90.14 millionOptionableRVLPRVL Pharmaceuticals125111.41 million106.50 millionOptionableATOS, RVLP, and PIRS HeadlinesSourceHeadlineRVLPQ RVL Pharmaceuticals plcseekingalpha.com - March 2 at 5:42 AMRVL Pharmaceuticals PLC RVLPQmorningstar.com - January 11 at 11:30 PMRVL Pharmaceuticals plc’s latest rating changes from various analystsknoxdaily.com - October 18 at 9:20 PMRVL Pharmaceuticals Shares Plummet 50% as Subsidiaries File For Bankruptcymarketwatch.com - October 13 at 6:11 PMSpecialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for Bankruptcybenzinga.com - October 12 at 3:12 PMRVL Subsidiaries To Effectuate Change Of Control; RVLP Ordinary Shares Expected To Be Cancelledmarkets.businessinsider.com - October 12 at 10:12 AMRVL Pharmaceuticals Subsidiaries File for Bankruptcyfinance.yahoo.com - October 12 at 10:12 AMRVL Pharmaceuticals plc [RVLP] Investment Guide: What You Need to Knowknoxdaily.com - October 11 at 11:29 PMWhy Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?investorplace.com - October 6 at 9:09 AMInvesting in RVL Pharmaceuticals plc [RVLP]: What You Must Knowknoxdaily.com - October 4 at 11:12 PMUnderstanding the Risks of Investing in RVL Pharmaceuticals plc (RVLP)knoxdaily.com - September 27 at 3:22 PMRVLP Shares Experience Surge in Valueknoxdaily.com - September 21 at 7:46 PMExamining the Potential Price Growth of RVL Pharmaceuticals plc (RVLP)knoxdaily.com - September 13 at 9:29 PMAnalysts predict RVLP shares will perform strongly in 2023knoxdaily.com - September 7 at 8:26 PMRVL Pharmaceuticals plc [RVLP] Investment Appeal on the Riseknoxdaily.com - August 23 at 6:58 PMUnmasking the Value Trap: A Deep Dive into RVL Pharmaceuticals PLCfinance.yahoo.com - August 23 at 6:58 PMRVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 23 at 6:58 PMRVL Pharmaceuticals (RVLP) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 21 at 6:25 PMCrude Oil Falls Sharply; RVL Pharmaceuticals Shares Plummetbenzinga.com - August 16 at 5:09 PMRVLP: Second Quarter Resultsmsn.com - August 16 at 5:09 PMRVL Pharmaceuticals Shares Hit New Lows After Stock Sale >RVLPmarketwatch.com - August 16 at 12:08 PMRVL Pharmaceuticals shares fall after pricing $5M stock offeringmsn.com - August 16 at 12:08 PMDowngrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near Termfinance.yahoo.com - August 16 at 12:08 PMRVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rulesfinance.yahoo.com - August 16 at 12:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Pieris PharmaceuticalsNASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.RVL PharmaceuticalsNASDAQ:RVLPRVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.